ライフサイエンスコーパス: heavy chain

1 ndividual contacts across the immunoglobulin heavy chain.

2 g heterozygous human mutations in the myosin heavy chain.

3 riphosphatase activity of the cardiac myosin heavy chain.

4 four closely spaced cysteine residues of the heavy chain.

5 nding site, located at the C terminus of the heavy chain.

6 the bikunin PG was unable to accept a single heavy chain.

7 ng capacity, ATPase activity, and the dynein heavy chain.

8 rmline with only one somatic mutation in the heavy chain.

9 reas S1-15 utilizes exclusively the variable heavy chain.

10 mentarity-determining region 3 of the HC33.1 heavy chain.

11 brane-bound forms of the immunoglobulin (Ig) heavy chain.

12 d and somatically mutated residues on the Ab heavy chain.

13 ctin and its C-terminal lobe with the myosin heavy chain.

14 performing immunostaining of neonatal myosin heavy chain.

15 d His231 in the hinge region of the IgG1 mAb heavy chain.

16 w and troponin T and carbonylation of myosin heavy chains.

17 k-in mice expressing germline-reverted VRC01 heavy chains.

18 iched with B cells expressing prototypic ANA heavy chains.

19 y to cysteine residues both on the light and heavy chains.

20 efficient heterodimerization of the antibody heavy chains.

21 eavage sites based on sequence analysis, and heavy chain 1 (HC1) was confirmed to be a substrate of t

22 zeta/delta, annexin A1/A3/A4/A5/A6, clathrin heavy chain 1, glyceraldehyde-3-phosphate dehydrogenase,

23 The protein consists of three subunits, heavy chain 1, heavy chain 2, and bikunin covalently joi

24 rs such as alpha smooth muscle actin, myosin heavy chain 11, and smooth muscle 22 alpha.

25 Divalent cations and heavy chain 2 are essential co-factors in this transfer

26 erminal differentiation (myogenin and myosin heavy chain 2) were increased on d 2 and 4 postinjury bu

27 n consists of three subunits, heavy chain 1, heavy chain 2, and bikunin covalently joined by a chondr

28 eavy chain donor (pre-IalphaI) with a single heavy chain 3 (HC3), which are also constitutively expre

29 n 1 in contrast to the commonly observed CDR heavy chain 3, providing a unique perspective into antib

30 The germline immunoglobulin (Ig) variable heavy chain 4-34 (VH4-34) gene segment encodes in humans

31 56 and rs1354187) within the dynein axonemal heavy chain 5 (DNAH5) gene (Pmeta-int = 3.6 x 10(-5) and

32 , GATA binding protein 4 (GATA4), and myosin heavy chain 6 (MYH6).

33 nd maternal alleles of MYH6, encoding myosin heavy chain 6, in 2 patients who developed right ventric

34 In parallel, mRNA expression of myosin heavy chain 7 and natriuretic peptide B is up-regulated

35 Elevated myosin heavy chain 7 mRNA expression is detected in left ventri

36 Thirteen variants in MYBPC3 and MYH7 (myosin heavy chain 7) were each identified >3 times and account

37 pheld(1) (up(1)), heldup(2) (hdp(2)), myosin heavy chain(7) (Mhc(7)), actin88F(KM88) (Act88F(KM88)),

38 show the identification of non-muscle myosin heavy chain 9 (MYH9) as an essential factor for PRRSV in

39 chemical inhibition of non-muscle myosin IIA heavy chain activity.

40 f immunoglobulin genes, thereby disrupting 1 heavy-chain allele.

41 osition of monoclonal Ig light chains and/or heavy chains along the glomerular and tubular basement m

42 llular cardiac antigens, like cardiac myosin heavy chain-alpha, cardiac troponin-I, and adenine nucle

43 jacent to both heavy chains and that the two heavy chains also were in close proximity.

44 cytes that transiently express atrial myosin heavy chain (amhc) contributes substantially to specific

45 ed heart-to-body weight ratios, alpha myosin heavy chain and cardiac isoprostane levels, suggesting t

46 e found that LdRab5b interacts with clathrin heavy chain and hemoglobin receptor.

47 comparison between the schistosome myosin II heavy chain and known striated muscle myosins.

48 nteraction for hRSV90 on RSV F, in which the heavy chain and light chain both have specific interacti

49 e of two interacting proteins, including the heavy chain and light chain of an antibody Fab.

50 MYH7 and MYBPC3, encoding beta-myosin heavy chain and myosin-binding protein C, respectively,

51 rks and did not show up-regulation of myosin heavy chain and myotube formation when grown in differen

52 class derive from the IGHV1-2 immunoglobulin heavy chain and neutralize a wide spectrum of HIV-1 stra

53 interacted with EB1, p150(Glued), and dynein heavy chain and was sufficient to critically alter the m

54 ractionated impurities, and their respective heavy chains and light chains and (2) middle-down LC/MS/

55 t is homologous to the rod portion of myosin heavy chains and resides in thick filament cores.

56 that bikunin was positioned adjacent to both heavy chains and that the two heavy chains also were in

57 ers with five glycosylation sites on the mu (heavy) chain and one glycosylation site on the J chain.

58 c cardiomyopathy (HCM) are MYH7 (beta-myosin heavy chain) and MYBPC3 (beta-myosin-binding protein C).

59 d function among wild type, Dnchc2 (dynein 2 heavy chain), and Wdr34 mutant cells demonstrates that c

60 the upper 50 kDa sub-domain of the myosin II heavy chain, and cells carrying this lethal mutation are

61 LdRab5a failed to interact with the clathrin heavy chain, and interaction with hemoglobin receptor wa

62 peptides derived from nebulin, titin, myosin heavy chains, and troponin I proteins, those showing the

63 ingle domain antibodies derived from camelid heavy chain antibodies.

64 Two myosin heavy chains are expressed in the myoepithelial sheath,

65 ain) and pNF-H (phosphorylated neurofilament-heavy chain) are normal before symptom onset and increas

66 C-terminal truncation at Gly93 and oxidized heavy chains at Met40, Met93, and Met430.

67 difficile mAb are degradation species of the heavy chains at residue Asn101 as well as at the hinge r

68 Human autoantibodies with IGHV4-34*01 heavy chains bind to poly-N-acetyllactosamine carbohydra

69 homologous protein (chop) and immunoglobulin heavy chain binding protein (bip) levels.

70 BiP (immunoglobulin heavy-chain binding protein) is the endoplasmic reticulu

71 R lumenal molecular chaperone immunoglobulin heavy-chain-binding protein (BiP) as limiting Ca(2+) lea

72 Reduced expression of the clathrin heavy chain by HCV prevents ENT1 recycling to the plasma

73 pted when modeling human beta-cardiac myosin heavy chain cardiomyopathy mutations E497D or R712L, imp

74 is dominated by aromatic residues in the 1G2 heavy chain CDR3 protruding into a hydrophobic cleft in

75 omprised of designed heavy and light or just heavy chain CDRs were synthesized and screened for pepti

76 We examined clathrin heavy chain (ClaH-GFP) which localized to three distinct

77 Immunoglobulin heavy chain class switch recombination (CSR) requires ta

78 , LV6-57 was more common, whereas KV3-20 and heavy-chain codeposition were less common in ALS In this

79 ting of substitutions L351D and L368E in one heavy chain combined with L351K and T366K in the other.

80 with HIV Env, and less hypermutation in the heavy chain, compared with antibodies using the kappa li

81 The ultralong heavy chain complementarity determining region 3 (CDR3H)

82 the formation of numerous interactions with heavy chain complementarity domain regions (CDRs) of HM1

83 332 and N301, VH4 family gene utilization, a heavy chain complementarity-determining region 2 (CDRH2)

84 The lineage Abs bore an anionic heavy chain complementarity-determining region 3 (CDRH3)

85 by germline encoded and immunoglobulin (Ig) heavy-chain complementarity determining region 3 (HCDR3)

86 CD6 Fab reveals a unique epitope, where the heavy-chain complementarity determining regions (HCDRs)

87 igh somatic mutation frequencies, long third heavy-chain complementarity determining regions, and/or

88 n of Abs with unusual features, such as long heavy-chain complementarity-determining region 3 (HCDR3)

89 ibody repertoire of cows contains long third heavy chain complementary determining regions (HCDR3) wi

90 e beta2-microglobulin interface on the MHC-I heavy chain, consistent with in vitro binding experiment

91 constant region, while zinc was bound to the heavy chain constant region and iron was not bound with

92 /17 variants in the immunoglobulin G1 (IgG1) heavy chain constant region, virus neutralization, and n

93 to both the transmembrane component and the heavy chain constant region, while zinc was bound to the

94 eight protein spots corresponding to the IgA heavy chain constant region.

95 was detected in between the light chain and heavy chain disulfide bond of the A and A/B forms.

96 osure; p=1.1x10-06), was annotated to Dynein Heavy Chain Domain 1 gene (DNHD1) which is highly expres

97 arental antibodies, each containing a single heavy chain domain mutation, are mixed and subjected to

98 how that AECs synthesize TSG-6 and their own heavy chain donor (pre-IalphaI) with a single heavy chai

99 d from human memory B cells, that utilizes a heavy chain encoded by the IGHV3-30 germline gene.

100 regions juxtaposed to active immunoglobulin heavy chain enhancer elements, chromosomal aneuploidy, s

101 le phenotype with rapid expression of myosin heavy chain, even in proliferative conditions.

102 ing factor beta and the smooth-muscle myosin heavy chain), expressed in AML with the chromosome inver

103 generating muscle, but only in type I myosin heavy chain-expressing cells.

104 Embryonic myosin heavy chain expression and central nucleation, indices o

105 as treatment with Torin 1, degrades clathrin heavy chain expression in a hepatoma cell line.

106 Fiber type (myosin heavy chain expression) and 2DG accumulation were measur

107 on was confirmed by uniform NCAM1 and myosin heavy chain expression.

108 ellular mediator [i.e., the protein ferritin heavy chain (FHC)] of HIV-induced dendritic damage and t

109 e light chain, which assembles with antibody heavy chain forming a pre-BCR, leads to production of an

110 Of 52 distinct allergen-specific IgE heavy chains from 8 allergic donors, 37 were also detect

111 This interaction leads to transfer of the heavy chains from the chondroitin sulfate of inter-alpha

112 HC-HA modification involves the transfer of heavy chains from the inter-alpha-inhibitor (IalphaI) pr

113 s eliminated 105 (human clotting factor VIII heavy chain [FVIII HC]) and 59 (polio VIRAL CAPSID PROTE

114 s the structure of the 2.8-Mb immunoglobulin heavy chain gene (IgH) locus in pro-B cells.

115 Variation in the human beta-cardiac myosin heavy chain gene (MYH7) can lead to hypertrophic cardiom

116 cells and unmutated immunoglobulin variable heavy chain gene have similarly been validated to predic

117 xpansion following successful immunoglobulin heavy chain gene rearrangement.

118 disabled mutation of the essential myosin-II heavy-chain gene (myo2-E1) and deletion mutations of the

119 g analysis of rearranged immunoglobulin (Ig) heavy chain genes from biological replicates, covering m

120 kinetics bat and songbird SFM express myosin heavy chain genes that are evolutionarily and ontologica

121 ) and deletion mutations of the other myosin heavy-chain genes.

122 s a heavily biased use of two immunoglobulin heavy chain germlines generated high affinity (pM) antib

123 nd/or a NIRF dye (FL) were conjugated to the heavy-chain glycans of 5B1, using a robust and reproduci

124 unological significance of BoNT/A C-terminal heavy chain (HC) and light chain (LC) domains were inves

125 ngth, are capable of accepting only a single heavy chain (HC) from inter-alpha-inhibitor via transfer

126 pment of novel antibody-based therapies, and heavy chain (Hc) heterodimers represent a major class of

127 nown subtype F5, while the C-terminus of the heavy chain (HC) most resembled the binding domain of se

128 hibits OPC maturation and complexes with the heavy chain (HC) of glycoprotein inter-alpha-inhibitor t

129 Both heavy chain (HC) residues Met257 and Met433 were located

130 erentiation, and mAb A38 (preventing IalphaI heavy chain (HC) transfer), HA-oligosaccharides, cobalt,

131 nked glycosylation sites: one present on the heavy chain (HC) variable region (Fab) and the other pre

132 n (LC) disulfide bond linked to a C-terminal heavy chain (HC) which includes a translocation domain (

133 I monoclonal antibodies (W6/32, TFL-006, and heavy chain (HC)-10).

134 where it may be covalently modified with the heavy chains (HC) of inter-alpha-trypsin inhibitor.

135 s required to transfer inter-alpha-inhibitor heavy chains (HC) to hyaluronan (HA), facilitating HA re

136 ibitor (IalphaI) proteoglycan, which has two heavy chains (HC1 and HC2) on its chondroitin sulfate ch

137 nto their ciliated apical surfaces to form a heavy chain hyaluronan (HC-HA) matrix in the absence of

138 Heavy chain-Hyaluronan/Pentraxin 3 (HC-HA/PTX3) is a com

139 Because heavy chain-hyaluronic acid/pentraxin 3 (HC-HA/PTX3) pur

140 list scaffold generated from camelid-derived heavy-chain IgGs, are one such example.

141 ion of the locus encoding the immunoglobulin heavy chain (Igh) and controlled expression of the gene

142 cers of the loci encoding the immunoglobulin heavy chain (Igh) and kappa-light chain (Igk) and, furth

143 yping, and deep sequencing of immunoglobulin heavy chain (IGH) and T-cell receptor delta (TRD) loci.

144 Bs) serve as obligatory intermediates for Ig heavy chain (Igh) class switch recombination (CSR).

145 As a master regulator of functional Ig heavy chain (IgH) expression, the IgH 3' regulatory regi

146 Ig heavy chain (IgH) isotypes (e.g., IgM, IgG, and IgE) are

147 susceptibility signal in the immunoglobulin heavy chain (IGH) locus centring on a haplotype of nonsy

148 Transcription at the immunoglobulin heavy chain (Igh) locus targets CSR-associated DNA damag

149 We identify the immunoglobulin heavy chain (IGH) locus to be associated with anti-PEG I

150 o IgE in human subjects using immunoglobulin heavy chain (IGH) mutational lineage data.

151 B cells that have acquired two nonproductive heavy chain (IgH) rearrangements.

152 Ig heavy chain (IgH) variable region exons are assembled fr

153 try analysis revealed that non-muscle myosin heavy chain II A (NMHC IIA) is a protein targeted by CLI

154 dy (m21G6) directed against nonmuscle myosin heavy chain II may inhibit IgM binding and reduce injury

155 hly conserved self-antigen, nonmuscle myosin heavy chain II, has been identified as a target of patho

156 MYH9 gene that encodes the nonmuscle myosin heavy chain IIA are associated with diabetic nephropathy

157 lipase, glutathione peroxidase-1, and myosin heavy chain IIa in quadriceps of control mice but not in

158 tified a new Rab3 effector, nonmuscle myosin heavy chain IIA, as part of the complex formed by Rab3a

159 ed by miR-200a, we focused on the non-muscle heavy chain IIb (NMHCIIb), and showed that miR-200a dire

160 rillarin, nuclear lamin B1, nonmuscle myosin heavy chain IIB, paxillin, Sec61 beta, tight junction pr

161 The ancillary testing included PCR for heavy chain immunoglobulin gene rearrangements, immunohi

162 NA loop, are formed in switch regions on the heavy-chain immunoglobulin locus.

163 We investigate how the deletion of clathrin heavy chain impairs the dynamics and the morphology of t

164 determining region 3 of each B cell receptor heavy chain in every patient repertoire as input to a de

165 G by coexpression of two different light and heavy chains in a single host cell is potentially more e

166 enriched for cells expressing prototypic ANA heavy chains in these mice in a non-autoimmune backgroun

167 y one head bound to one of the two identical heavy-chains in the asymmetrically bent IgE-Fc.

168 fied a role for DHC-1, the C. elegans dynein heavy chain, in maintaining neuronal cargo distribution.

169 the heavy chain, unlike MTIP that bound the heavy chain independently of PfELC.

170 ansferase 110 kDa subunit (OGT1) and kinesin heavy chain isoform 5A and alterations in the non-miR-18

171 Myosin heavy chain isoform composition of muscle samples did no

172 -10, chemokine receptors, and immunoglobulin heavy-chain isotypes, was measured.

173 pidopteran Trichoplusia ni KLC and kinesin-1 heavy chain (KHC) by coimmunoprecipitation and colocaliz

174 Recently, we have shown that kinesin-1 heavy chain (KHC) can transport one microtubule on anoth

175 mutation into the genomic locus of kinesin-1 heavy chain (KHC), generating the Khc(mutA) allele.

176 sin-1 can function as a dimer of two kinesin heavy chains (KHC), which harbor the motor domain, or as

177 Thus, like the motor-bearing kinesin heavy chains, KLCs exist in a dynamic conformational sta

178 At the Ig heavy chain locus (IgH), a nucleosome in pro-B cells is

179 strand DNA mutagenesis at the immunoglobulin heavy chain locus and some other regions of the B cell g

180 Quantitative deep sequencing of the Ig heavy chain locus from B220(+)CD43(+) populations identi

181 rrent translocations into the immunoglobulin heavy chain locus.

182 Immunoglobulin heavy-chain locus V(D)J recombination requires a 3D chro

183 d Rag1/2, which are critical for the IgH (Ig heavy-chain) locus contractions and rearrangement.

184 For the analyzed heavy chain marker peptides deuterium uptake differences

185 using Arg403Gln mutation in the alpha-myosin heavy chain (MHC) gene is inhibited by doxycycline admin

186 ross sectional area and proportion of myosin heavy chain (MHC) IIB and low succinate dehydrogenase (S

187 ng velocities, and/or a difference in myosin heavy chain (MHC) isoform content in chimpanzee relative

188 rcomeres and capable of deacetylating myosin heavy chain (MHC) isoforms.

189 To investigate myosin heavy chain (MHC) phosphorylation roles in 3D migration,

190 samples made without salt (Lot A), no myosin heavy chain (MHC) polymerization was observed, only aggr

191 endogenous MyoD, Myogenin, and Myh3 (myosin heavy chain, [MHC] gene) mRNAs but not the cognate prote

192 generate BsAbs without heavy/heavy and light/heavy chain mispairing.

193 Kinesin heavy chains move cargo along microtubules by one of man

194 egulated SM22, SM alpha-actin, and SM myosin heavy chain mRNA and protein levels.

195 ol in Longissimus dorsi muscle, where myosin heavy chain (MYH) was significantly up-regulated.

196 otein-altering mutations in embryonic myosin heavy chain (MYH3) in three families.

197 associated with mutations in the beta-myosin heavy chain (MYH7) gene product (Myosin-7).

198 failed to express some characteristic myosin heavy chain (MyHC) proteins.

199 naive B cells expressing the human germline heavy chain of 3BNC60, paired with endogenous mouse ligh

200 DYNC1H1 encodes the heavy chain of cytoplasmic dynein-1, a 1.4-MDa motor com

201 Remarkably, tagging of the heavy chain of dynein 1 (DYNC1H1) shows this mRNA accumu

202 ed by persistent expression of the secretory heavy chain of immunoglobulin M (micros), is well-tolera

203 Here we show that the heavy chain of kinesin-1 directly interacts with the APC

204 we demonstrate that mice lacking Kif5b (the heavy chain of kinesin-1) in hematopoietic cells are les

205 erization and Met56 oxidation in CDR2 in the heavy chain of mAb1 result in opposing conformational im

206 anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-spec

207 Here we identified a mutation in dhc-1, the heavy chain of the cytoplasmic dynein minus-end directed

208 onsolidation genetic knockdown of Myh10, the heavy chain of the most highly expressed NMII in the BLC

209 osome pull-down screen identifies KIF5B, the heavy chain of the motor protein kinesin-1, as a new PA-

210 expressing the predicted germline or mature heavy chains of a potent bNAb to the CD4 binding site (C

211 molecule that binds Fcgamma and VH3 variant heavy chains of Ig.

212 variable and constant domains of the feline heavy chains of IgG1a (IGHG1a), IgG2 (IGHG2), and IgA (I

213 Both the light and the heavy chains of the antibodies are important in binding

214 eoside-modified mRNAs encoding the light and heavy chains of the broadly neutralizing anti-HIV-1 anti

215 to the influence of different regions of the heavy chain on dynein motility.

216 stimulates phosphorylation of the NM myosin heavy chain on Ser1943 and causes NM myosin filament ass

217 stimulated the phosphorylation of NM myosin heavy chain on Ser1943 in tracheal SM tissues, which can

218 applications, nanobodies (VHH) derived from heavy chain only antibodies from Camelidae, may be bette

219 Ly-6G-specific variable fragments of camelid heavy chain-only antibodies (VHH) conjugated to Pseudomo

220 Variable domains of camelid heavy chain-only antibodies (VHHs) with affinity for PA

221 igen-recognizing domains of the minimalistic heavy chain-only antibodies produced by camels and llama

222 GPI-anchored variable regions (VHHs) of two heavy chain-only antibodies, JM2 and JM4, from immunized

223 The variable regions (VHHs) of two heavy chain-only antibodies, JM2 and JM4, from llamas th

224 From a library of heavy chain-only antibody fragments (VHHs), we isolated

225 All heavy chain-only antibody variable domains bind HypE whe

226 duction, the recombinant variable domains of heavy-chain-only antibodies (VHHs) are becoming a salien

227 Nanobodies, which are derived from unique heavy-chain-only antibodies, are the smallest antigen-bi

228 oNT/A1 termed ciA-C2, derived from a camelid heavy-chain-only antibody (VHH).

229 t the production and evaluation of a camelid heavy-chain-only VH domain (VHH)-based neutralizing agen

230 and GIPR were fused to the N-terminus of the heavy chain or light chain of an antibody, either alone

231 ractions mediating binding to site VIII, the heavy chain overlaps with site O, and the light chain in

232 tation in CLTCL1 encoding the CHC22 clathrin heavy chain, p.E330K, which we demonstrate to have a fun

233 and accurate quantification of all light and heavy chain pairing variants in a mixture of bispecific

234 o promote efficient and stable cognate light-heavy chain pairing.

235 chanoenzyme myosin II, independent of myosin heavy-chain phosphorylation, thus increasing cellular co

236 n to CSF markers (NF-L and phosphorylated NF heavy chain (pNF-H), tau, S100B, 14-3-3) and prion conve

237 that levels of phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict

238 Phosphorylated neurofilament heavy chain (pNfH) levels are elevated in cerebrospinal

239 ress the effect of absence of NaCl on myosin heavy chain polymerization during two-step surimi gelati

240 n CDR3 signature and VRC01-like neutralizing heavy-chain precursors that rapidly matured within 2 yea

241 sgenic mouse model expressing germline VRC01 heavy chains produced broad neutralization of near-nativ

242 n before somatic hypermutation, and antibody heavy chain production, but the functional ranking of it

243 n by the cardiomyocyte-specific alpha-myosin heavy chain promoter.

244 ing domain reveals that its IGHV1-69-derived heavy chain provides more than 85% binding surface and t

245 punctuated by clones expressing the variable heavy-chain region VH4-34 that produced dominant serum a

246 show that the BM plasma cell immunoglobulin heavy chain repertoire is remarkably stable over time.

247 ntract while the diversity of immunoglobulin heavy chain repertoire recovers.

248 Surprisingly, PfELC binding to the heavy chain required that MTIP also be bound to the heav

249 inds lipid A through both variable light and heavy chain residues, whereas S1-15 utilizes exclusively

250 ducible short hairpin RNA targeting clathrin heavy chain, resulting in approximately 85% protein loss

251 These mice were crossed with alpha-myosin heavy chain reverse transcriptional transactivator trans

252 the beta-cardiac/slow skeletal muscle myosin heavy chain rod.

253 se-sensitive sites in the antibody light and heavy chain sequences.

254 utation in IgG (P = .003) but not IgA or IgM heavy chain sequences.

255 myosin RLC phosphorylation and by NM myosin heavy chain Ser1943 phosphorylation.

256 raction between CBFbeta-smooth muscle myosin heavy chain (SMMHC; encoded by CBFB-MYH11) and RUNX1 pla

257 end-diastolic flow contained reduced myosin heavy chain, smooth muscle actin, and desmin, and increa

258 eight correlated positively with CSE, myosin heavy chain, smooth muscle actin, and desmin, and negati

259 CSE correlated positively with myosin heavy chain, smooth muscle actin, and desmin.

260 Younger age and mutated immunoglobulin heavy chain status were significant risk factors for the

261 beta2m-free B27 heavy chain structures including homodimers (B272) can a

262 eased alpha myosin and increased beta myosin heavy chains, suggesting an alpha-to-beta conversion wit

263 marked by dysregulation of embryonic myosin heavy chain temporal expression.

264 , but residues in the N-terminal part of the heavy chain, the gamma-loop, and anion-binding exosite 1

265 The region around the N-terminus of the heavy chain, the Na(+)-binding loop, and the 170 s loop,

266 light meromyosin (LMM) region of the myosin heavy chain, the underlying molecular mechanism causing

267 fused to various proteins including antibody heavy chains, the N-terminal fragment of Cfa exhibits in

268 ent-accessible surface area; and (iv) public heavy-chain third complementarity-determining region (CD

269 bited the interaction between Lva and dynein heavy chain, thus disrupting the recruitment of dynein t

270 phorylation of non-muscle Myosin IIA (NMIIA) heavy chain, thus facilitating NMIIA association with Go

271 he membrane-bound form of the immunoglobulin heavy chain to its secreted form by activating Ell2 (whi

272 sing the linker length between the light and heavy chains to improve display and bacterial expression

273 a phylogenetic distance metric to analyze Ig heavy-chain transcript sequences in both young and elder

274 hain required that MTIP also be bound to the heavy chain, unlike MTIP that bound the heavy chain inde

275 le-down LC/MS/MS of the light chains and the heavy chains using higher energy C-trap dissociation (HC

276 By screening a single-domain heavy chain (V(H)H) library raised against TcdB, we iden

277 .9% for patients with mutated immunoglobulin heavy chain variable (IGHV) gene (IGHV-M) and 8.7% for p

278 hanges are more pronounced in immunoglobulin heavy chain variable (IGHV)-unmutated CLL cells than IGH

279 ultivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and tri

280 features: 94% with unmutated immunoglobulin heavy chain variable gene rearrangement, 58% with del(17

281 xa and Puma, independently of immunoglobulin heavy chain variable region mutational status, CD38, and

282 neDB, a system for analyzing vast amounts of heavy chain variable region sequences and exploring the

283 repertoire sequencing of immunoglobulin (Ig) heavy chain variable regions (VH) from CSF and subsorted

284 proline at position 41, a non-CDR residue in heavy chain variable regions (VH), is important for huma

285 mphocytic leukemia (CLL), the immunoglobulin heavy-chain variable (IgVH) region may be mutated (Ig-mu

286 letion, and 75% had unmutated immunoglobulin heavy-chain variable genes.

287 -CLL) or mutated (M-CLL) immunoglobulin gene heavy-chain variable region (IGHV) displays different st

288 the mutational status of the immunoglobulin heavy-chain variable region are important in clinical ma

289 Ig heavy-chain variable region exons are assembled developm

290 view, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status

291 treatment irrespective of the immunoglobulin heavy-chain variable-region gene (IGHV) mutational statu

292 high-throughput sequencing of immunoglobulin heavy chain VDJ rearrangements of naive, mature CD5(+),

293 MEDI8852 uses the heavy-chain VH6-1 gene and has higher potency and breadt

294 of the anti-IL-13 light chain to its cognate heavy chain was observed, which may be leveraged to guid

295 dy recognizing an intrinsically autoreactive heavy chain, we show enrichment in self-reactive cells s

296 ld lower the denaturation of crayfish myosin heavy chain when compared to the control.

297 a result, methionine at position 258 of the heavy chain, which is located in the C(H)2 domain of the

298 light chain (RLC) binding site in the myosin heavy chain with concomitant dissociation of the RLC.

299 jority of infected lymphocytes expressed IgM heavy chains with Iglambda light chains, recapitulating

300 e fragment crystallizable (Fc) region of the heavy chain, with a net mass increase of 14 Da.